1. In Vivo
  2. >>ESG
  3. >>Diversity & Inclusion

How Can Pharma Seek To Discuss Gender Diversity?

Communications Ought To Be Both Accessible And Inclusive

 
• By Chloe Kent

As gender-neutral language becomes more widely used throughout the business community, the pharmaceutical industry must confront how it approaches the matter of gendered language in healthcare communications.

Symbols of man, woman and transgender on dark background
While often used synonymously, sex and gender are not the same thing. • Source: Shutterstock

Gender-neutral language is increasingly being adopted across different industries, including in certain health care and pharmaceutical communications, to be more inclusive towards a wider range of people. By using terms such as “individuals with a prostate” or “patients with breast cancer,” the communications in question are aiming to consider the experiences of transgender individuals, whose gender identity is different to their physical sex.

Clarifying Language Used In This Article

Though often used synonymously, the categories of sex and gender are not one and the same thing. While sex refers to the nature of an individual’s biology, whether they...

For example, “individuals with a prostate” is inclusive of both cisgender men and trans people with the same anatomy. Meanwhile, “patients with breast cancer” can be said to do a...

More from Diversity & Inclusion

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 
• By Anabel Costa-Ferreira

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By Brian Yang

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Infographic: Analyzing The Gap In Women’s Health Care

 
• By Anabel Costa-Ferreira

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By Ed Silverman

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

More from ESG

Global Regulator Action To Improve Diversity In Clinical Trials

 
• By Vibha Sharma

As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment. 

Providing The Balance Between Medtech Innovation And Providers’ Sustainability

 
• By Ashley Yeo

Royal Philips is at the forefront of the driving environmental sustainability along the Scope 1-2-3 chain. The company hosted a round table in Amsterdam to hear experiences from providers.

FDA Publishes Updated Roadmap For Advancing Women’s Health

 
• By Brian Bossetta

The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.